临床药师在他汀类药物引起的横纹肌溶解症中的药学服务
|
摘要
目的:探索临床药师在他汀类药物引起的横纹肌溶解症(rhabdomyolysis)中的药学服务。方法:临床药师参与3例他汀类药物引起的横纹肌溶解症治疗的案例,分析并总结临床药师在其中的药学服务方式。结果:临床药师对他汀类药物引起的横纹肌溶解症进行监护与分析,并进行关联性评价,分析其高危因素,并提供相应的药学服务。结论:临床药师可在他汀类药物引起的横纹肌溶解症的关联性评价,关注高危因素,提供用药教育等切入点为临床提供药学服务。
AIM: To explore the pharmaceutical services of clinical pharmacists in rhabdomyolysis caused by statins. METHODS: Clinical pharmacist participated in the assessment and treatment of three patients of rhabdomyolysis caused by statins,analyzed and summarized the pharmaceutical services of clinical pharmacists in it. RESULTS: Clinical pharmacists provided Pharmaceutical Care of rhabdomyolysis caused by statins,conducted the relevance evaluation of Adverse Drug Reactions,analyzed the risk factors of rhabdomyolysis caused by statins,and offered corresponding pharmaceutical services.CONCLUSION: Clinical pharmacists can provide pharmaceutical service on entry point of relevance evaluation of Adverse Drug Reactions,focusing on risk factors,giving Medical education in rhabdomyolysis patients induced by statins.
AIM: To explore the pharmaceutical services of clinical pharmacists in rhabdomyolysis caused by statins. METHODS: Clinical pharmacist participated in the assessment and treatment of three patients of rhabdomyolysis caused by statins,analyzed and summarized the pharmaceutical services of clinical pharmacists in it. RESULTS: Clinical pharmacists provided Pharmaceutical Care of rhabdomyolysis caused by statins,conducted the relevance evaluation of Adverse Drug Reactions,analyzed the risk factors of rhabdomyolysis caused by statins,and offered corresponding pharmaceutical services.CONCLUSION: Clinical pharmacists can provide pharmaceutical service on entry point of relevance evaluation of Adverse Drug Reactions,focusing on risk factors,giving Medical education in rhabdomyolysis patients induced by statins.
引文
[1]Tonelli M,Lloyd A,Clement F,etal.Efficacy of statins for primary prevention in people at low cardiovascular risk:a meta-analysis[J].CMAJ,2011,183(16):E1189-1202.
[2]Joy TR,Hegele RA.Narrative review:statin-related myopathy[J].Ann Intern Med,2009,150(12):858-868.
[3]Khan FY.Rhabdomyolysis:a review of the literature[J].Neth J Med,2009,67(9):272-283.
[4]Torres PA,Helmstetter JA,Kaye AM,etal.Rhabdomyolysis:pathogenesis,diagnosis,and treatment[J].Ochsner J,2015,15(1):58-69.
[5]Graham DJ,Staffa JA,Shatin D,etal.Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs[J].JAMA,2004,292:2585-2590.
[6]江岳鑫,娄莹,刘玉清,等.他汀类药物致160例肌病相关不良反应的临床分析[J].中华高血压杂志,2014,42:(11):905-909.
[7]黄惠明.2008-2013年他汀类药物致横纹肌溶解症文献分析[J].中国药物应用与监测,2014,11(2):107-110.
[8]Albayda J,Christopher-Stine L.Identifying statin-associated autoimmue necrotizing myopathy[J].Cleve Clin J Med,2014,81:736-741.
[9]Vrablik M,Zlatohlavek L,Stulc T,etal.Statin-associated myopathy:from genetic predisposition to clinical management[J].PhysiolRes,2014,63Suppl3:S327-334.
[10]Abramson JD,Rosenberg HG,Jewel N,etal.Should people at low risk of cardiovascular disease take a statin[J]?BMJ,2013,347:f6123.
[11]刘建平,邢建民.循证的药品不良反应评价方法[J].中国药物警戒,2010,7(1):12-15.
[12]Ramkumar S,Raghunath A,Raghunath S.Statin Therapy:Review of Safety and Potential Side Effects[J].Acta Cardiol Sin,2016,32(6):631-639.
[13]Huerta-Alardn AL,Varon J,Marik PE.Bench-tobedside review:Rhabdomyolysis-an overview for clinicians[J].Crit Care,2005,9(2):158-169.
[14]Bruckert E,Hayem G,Dejager S,etal.Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study[J].Cardiovasc Drugs Ther,2005,19(6):403-414.
[15]Frydrychowicz C,Pasieka B,Pierer M,etal.Colchicine triggered severe rhabdomyolysis after long-term low-dose simvastatin therapy:a case report[J].J Med Case Rep,2017,11(1):8-13.
[16]Duncan SJ,Howden CW.Proton Pump Inhibitors and Risk of Rhabdomyolysis[J].Drug Saf,2017,40(1):61-64.
[17]Li DQ,Kim R,Mc Arthur E,etal.Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4[J].CMAJ,2015,187(3):174-180.
[18]Hirota T,Ieiri I.Drug-drug interactions that interfere with statin metabolism[J].Expert Opin Drug Metab Toxicol,2015,10:1-13.
[19]Blaier O,Lishner M,Elis A.Managing statin-induced muscle toxicity in a lipid clinic[J].J Clin Pharm Ther,2011,36(3):336-341.
[20]Simons JE,Holbrook AM,Don-Wauchope AC.Successful reintroduction of statin therapy after statin-associated rhabdomyolysis[J].J Clin Lipidol,2015,9(4):594-596.
[21]熊贤兵,李刚,罗文艳,等.1例辛伐他汀联用罗红霉素致横纹肌溶解患者的药学监护[J].中南药学,2015,13(6):660-662.
[22]中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J].中国循环杂志,2016,31(10):937-953.
[2]Joy TR,Hegele RA.Narrative review:statin-related myopathy[J].Ann Intern Med,2009,150(12):858-868.
[3]Khan FY.Rhabdomyolysis:a review of the literature[J].Neth J Med,2009,67(9):272-283.
[4]Torres PA,Helmstetter JA,Kaye AM,etal.Rhabdomyolysis:pathogenesis,diagnosis,and treatment[J].Ochsner J,2015,15(1):58-69.
[5]Graham DJ,Staffa JA,Shatin D,etal.Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs[J].JAMA,2004,292:2585-2590.
[6]江岳鑫,娄莹,刘玉清,等.他汀类药物致160例肌病相关不良反应的临床分析[J].中华高血压杂志,2014,42:(11):905-909.
[7]黄惠明.2008-2013年他汀类药物致横纹肌溶解症文献分析[J].中国药物应用与监测,2014,11(2):107-110.
[8]Albayda J,Christopher-Stine L.Identifying statin-associated autoimmue necrotizing myopathy[J].Cleve Clin J Med,2014,81:736-741.
[9]Vrablik M,Zlatohlavek L,Stulc T,etal.Statin-associated myopathy:from genetic predisposition to clinical management[J].PhysiolRes,2014,63Suppl3:S327-334.
[10]Abramson JD,Rosenberg HG,Jewel N,etal.Should people at low risk of cardiovascular disease take a statin[J]?BMJ,2013,347:f6123.
[11]刘建平,邢建民.循证的药品不良反应评价方法[J].中国药物警戒,2010,7(1):12-15.
[12]Ramkumar S,Raghunath A,Raghunath S.Statin Therapy:Review of Safety and Potential Side Effects[J].Acta Cardiol Sin,2016,32(6):631-639.
[13]Huerta-Alardn AL,Varon J,Marik PE.Bench-tobedside review:Rhabdomyolysis-an overview for clinicians[J].Crit Care,2005,9(2):158-169.
[14]Bruckert E,Hayem G,Dejager S,etal.Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study[J].Cardiovasc Drugs Ther,2005,19(6):403-414.
[15]Frydrychowicz C,Pasieka B,Pierer M,etal.Colchicine triggered severe rhabdomyolysis after long-term low-dose simvastatin therapy:a case report[J].J Med Case Rep,2017,11(1):8-13.
[16]Duncan SJ,Howden CW.Proton Pump Inhibitors and Risk of Rhabdomyolysis[J].Drug Saf,2017,40(1):61-64.
[17]Li DQ,Kim R,Mc Arthur E,etal.Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4[J].CMAJ,2015,187(3):174-180.
[18]Hirota T,Ieiri I.Drug-drug interactions that interfere with statin metabolism[J].Expert Opin Drug Metab Toxicol,2015,10:1-13.
[19]Blaier O,Lishner M,Elis A.Managing statin-induced muscle toxicity in a lipid clinic[J].J Clin Pharm Ther,2011,36(3):336-341.
[20]Simons JE,Holbrook AM,Don-Wauchope AC.Successful reintroduction of statin therapy after statin-associated rhabdomyolysis[J].J Clin Lipidol,2015,9(4):594-596.
[21]熊贤兵,李刚,罗文艳,等.1例辛伐他汀联用罗红霉素致横纹肌溶解患者的药学监护[J].中南药学,2015,13(6):660-662.
[22]中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J].中国循环杂志,2016,31(10):937-953.